用人工智能解释和图形神经网络来发现2型糖尿病认知障碍的危险因素和药物发现
Xin Zhang1, Jiajia Xie2, Xiong You3
1Department of Pediatric, The First Affiliated Hospital of Hunan College of Traditional Chinese Medicine, Zhuzhou, China.
Frontiers in endocrinology
|September 11, 2023
概括
糖尿病认知障碍 (CI) 影响许多患者,但其原因尚不清楚. 这项研究确定了糖尿病持续时间和年龄等危险因素,以及使用人工智能和图形神经网络的潜在治疗方法,包括梅特福林.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 计算生物学 计算生物学
背景情况:
- 认知障碍 (CI) 影响了全球约3.82亿糖尿病患者中的30%左右.
- 与糖尿病相关的CI机制在很大程度上是未知的,目前没有早期诊断或有效的治疗选择.
- 这项研究解决了对2型糖尿病 (T2DM) 中CI的理解和管理的关键需求.
研究的目的:
- 调查T2DM患者与CI相关的风险因素.
- 为了选T2DM-CI的潜在治疗药物.
- 建立一个预防和治疗T2DM-CI的基础.
主要方法:
- 收集了719名T2DM患者 (2018-2022) 的社会人口统计和临床数据.
- 利用六个机器学习算法和沙普利方法来识别T2DM-CI风险因素.
- 开发了一个图形神经网络 (GNN) 模型,以发现T2DM-CI的潜在治疗药物.
主要成果:
- 一个基于Catboost的风险预测模型实现了0.95的AUC,将糖尿病持续时间,年龄,教育,AST,饮酒和肠道微生物群确定为关键风险因素.
- 在GNN模型中,Metformin,Liraglutide和Lixisenatide被确定为T2DM-CI的潜在药物.
- 这项研究阐明了草药干预调节肠道微生物群的机制.
结论:
- 可解释的AI和GNN模型有效地识别T2DM-CI的风险因素和潜在治疗剂.
- 这种方法为糖尿病患者早期发现和治疗认知障碍提供了一种新的策略.
- 这些发现为有针对性的干预措施铺平了道路,以减轻T2DM-CI.CI的负担.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
151
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
151
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Psychoneuroimmunology: Diabetes and Cancer
47
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
47
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


